ABSTRACT Adult, male, unmedicated twins received antipyrine orally under carefully controlled environmental conditions. Relative contributions of genetic and environmental factors to 2-fold interindividual variations in rate constants for formation of the three main antipyrine metabolites were compared. Heritabilities for rate constants for formation of4-hydroxyantipyrine, Ndemethylantipyrine, and 3-hydroxymethylantipyrine were 0.88, 0.85, and 0.70, respectively. These results suggest that each molecular form of cytochrome P-450 that converts antipyrine to a different metabolite exhibits genetically controlled interindividual variations in activity. Unrelated adult male subjects whose environments were also carefully controlled exhibited highly reproducible rate constants for formation of antipyrine metabolites. Because the rate constant for metabolite formation sensitively detects certain variations in the gene product, it should be used in future pharmacogenetic studies on rates of production of multiple metabolites from a single parent drug.
In 1968, causes of large interindividual variations in rates of antipyrine (AP) decay in normal adults were identified in monozygotic (MZ) and dizygotic (DZ) twins (1) . Interindividual variations in AP clearance were maintained mainly by genetic factors. The twins lived in different households under nearly basal conditions with respect to multiple environmental factors capable of altering rates of AP clearance. In contrast to large interindividual variations, AP clearance in a given subject was highly reproducible, provided that no significant environmental perturbations occurred.
The twin study reported 13 years ago measured only plasma AP kinetics (1) . Because AP is degraded through multiple reactions catalyzed by enzymes independently influenced by numerous genetic and environmental factors, each metabolic pathway needs to be investigated separately. This approach, which was the objective of the present study, permitted a more specific estimate of gene activity than did the earlier study.
In several species, including man, three primary metabolites ofAP have been identified: 3-hydroxymethyl-AP, N-demethyl-AP, and 4-hydroxy-AP (2) (3) (4) (5) . Each metabolite is formed by a separate hepatic cytochrome P450-mediated monooxygenase (6, 7) . Conjugation then occurs to varying extents with glucuronide, rendering products even more water soluble and hence more easily excreted in urine where metabolites are identified (2) (3) (4) (5) (6) (7) (8) . In the present study, under carefully controlled environmental conditions, the relative roles of heredity and environment in controlling large interindividual variations in rates of hepatic formation of each AP metabolite were assessed in twins by using new sensitive techniques for metabolite detection. These data were used to test different pharmacokinetic models of AP elimination.
MATERIALS AND METHODS
Selection of Subjects. Ten unrelated subjects, 10 pairs of MZ twins, and 10 pairs of DZ twins between the ages of 16 and 35 yr without previous serious illness were obtained from Hershey and vicinity through advertisements in local newspapers. The subjects were nonsmoking, unmedicated, Caucasian males. All subjects were in a nearly basal state with regard to numerous environmental factors capable of affecting rates of AP metabolism (9) . Zygosity was determined by analysis of 10 erythrocyte antigens.
Sample Collection. At 0800, after a 12-hr fast, all subjects ingested AP (18 mg/kg) dissolved in 150 ml of water. Saliva samples (stimulated by chewing of Parafilm) were collected 3, 6, 9, 12, 15, and 24 hr after AP administration. Urine was collected over the following intervals: 0-4, 4-8, 8-12, 12-16, 16-24, 24-32, 32-40, 40-48, 48-56, 56-64, and 64-72 hr. Sodium metabisulfite (4 mg/ml) was added to each urine sample. Aliquots of urine were frozen at -700C until analyzed (no longer than 4 weeks). AP was administered again to each subject 2 weeks after the first dose, and again 4 weeks later to the 10 unrelated subjects, to determine the reproducibility of the kinetic values. All subjects abstained from food and drink containing caffeine, methylxanthines, or alcohol during the 4-day study.
Assay of AP and AP Metabolites. AP was extracted from 1 ml of saliva by using the procedure of Prescott et aL (10) . Metabolites were extracted from 1 ml of urine by the method of Danhof et aL (8) . Metabolites and AP were separated by highpressure liquid chromatography (Waters 8000A) and quantitated by an integrating recorder (Hewlett-Packard). The columns (10 cm X 2.8 mm) were packed in our laboratory with Lichrosorb RP-2 (mean particle size, 5 sum) by using a commercial column packer (Micromeritics, Norcross, GA). To prevent loss of N-demethyl-AP through adsorption to glass, all glassware in contact with AP metabolites was coated with a silicone preparation. Linear standard curves were generated by We used a new purer standard for 3-hydroxymethyl-AP kindly provided by D. D. Breimer. Breimer's older standards (8) were contaminated with sodium bromide to the extent of 55% by weight. Thus, values for percent AP recovered as urinary 3-hydroxymethyl-AP described in this paper are approximately half those reported in ref. 8 .
Pharmacokinetic Analysis. Development of meaningful measurements of the activity of each hepatic enzyme that produces a different AP metabolite requires a parameter that reAbbreviations: AP, antipyrine; MZ, monozygotic; DZ, dizygotic.
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The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. flects, as specifically as possible, the rate of formation of each metabolite. The rate constant, k, appears to be most appropriate in this regard. According to Brodie and Axelrod (3) and Vesell et al. (11) , the disposition of AP and its metabolites can be described by a series of monoexponential equations. These and subsequent studies demonstrated that AP and its metabolites conform to a one-compartment model with parallel, simultaneously occurring, first-order reactions in which metabolite excretion is faster than metabolite formation (Fig. 1) . Thus: log (rate of excretion)1 = log (ki dose) -230e3 [1] in which ki is the rate constant for formation ofthe ith metabolite and ke is the overall rate constant describing AP elimination (ke = kx + k1 + k2 + k3 + k4) (12) .
The first-order rate constant for metabolite production (k,) can be obtained from urinary excretion data by extrapolating to 0 the linear portion of the curve generated from Eq. 1 
.4, 16.1 ± 3.4, and 2.1 ± 0.7, respectively, in twins. These values are consistent with those reported previously (8, 13, 14) .
Reproducibility of rate constant measurements in a given subject was established by analysis of variance designed for repeated measurements in the 10 unrelated subjects who received AP three times. Intraindividual variations remained small and did not reach statistical significance (P > 0.05), but interindividual variations exceeded 2-fold for each AP metabolite (P < 0.05).
Estimates of heritability from metabolite rate constants, ki, in 40 twins revealed substantial genetic control over interindividual variations. H2 was 0.88, 0.85, and 0.70 for 4-hydroxy-AP, N-demethyl-AP, and 3-hydroxymethyl-AP, respectively (P < 0.05). H2 of the overall rate constant, ke was 0.77 ( Table   1 ).
The basic assumptions in the estimation of rate constants for formation of 4-hydroxy-AP, N-demethyl-AP, and 3-hydroxymethyl-AP were that (i) disposition of AP and its main metabolites followed a series of parallel, simultaneously occurring, first-order reactions with excretion being faster than formation, and (ii) absorption of orally administered solutions of AP was rapid and complete such that postabsorption plasma concentrations agreed with plasma concentrations found after intravenous administration of a similar dose (15) . Under these conditions, plots of logarithm of rate of excretion of these three metabolites versus time for any individual should yield parallel lines with slope = ke. Figs. 2 and 3 show that this expectation was fulfilled. Fig. 2 shows high reproducibility ofexcretion rates in four unrelated subjects. Fig. 3 and Table 1 demonstrate close similarity of excretion rates within most MZ twinships and dissimilarity within most DZ twinships. DISCUSSION These results show that genetically controlled variations in plasma AP half-life (1) arise from genetically controlled interindividual differences in rates of hepatic production of each major AP metabolite. The evidence indicates that each AP metabolite is produced by a separate molecularform ofcytochrome P-450 (6, 7). Our results suggest that each molecular form involved in AP metabolism exhibits genetically controlled differences in activity among normal uninduced adult subjects investigated under carefully controlled environmental conditions. Several previous pharmacogenetic studies utilized measurement of metabolites rather than of the parent drug alone. For example, twin studies on the urinary metabolites of halothane (16) and nortryptyline (17) led to conclusions similar to those of the present investigation. A study on amobarbital kinetics in twins (18) , although not reporting rate constants of metabolite formation, led to afollow-up family study in which rate constants for metabolite formation were measured (19) . No Proc. Natl, Acad. Sci. USA 78 (1981) 
